Jim Simons Rapt Therapeutics, Inc. Transaction History

Renaissance Technologies LLC

$63.6 Billion
Q1 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Rapt Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 98,000 shares of RAPT stock, worth $298,900. This represents 0.0% of its overall portfolio holdings.

Number of Shares

98,000

Holding current value

$298,900

% of portfolio

0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$6.87 - $26.45 $673,260 - $2.59 Million	98,000 New	98,000 $880,000
Q2 2023 Aug 11, 2023	SELL	$16.06 - $21.61 $918,631 - $1.24 Million	-57,200 Reduced 52.72%	51,300 $959,000
Q1 2023 May 12, 2023	BUY	$17.19 - $30.8 $1.31 Million - $2.35 Million	76,200 Added 235.91%	108,500 $1.99 Million
Q4 2022 Feb 13, 2023	BUY	$16.28 - $24.6 $42,328 - $63,960	2,600 Added 8.75%	32,300 $640,000
Q3 2022 Nov 14, 2022	BUY	$17.96 - $30.46 $533,412 - $904,662	29,700 New	29,700 $715,000

Q2 2022 Aug 12, 2022	SELL	$10.26 - $23.59 $466,830 - $1.07 Million	-45,500 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$17.02 - $40.22 $452,732 - $1.07 Million	26,600 Added 140.74%	45,500 $1 Million
Q4 2021 Feb 11, 2022	SELL	$29.5 - $39.5 $569,350 - $762,350	-19,300 Reduced 50.52%	18,900 $694,000
Q3 2021 Nov 12, 2021	BUY	$29.86 - $39.47 $1.14 Million - $1.51 Million	38,200 New	38,200 $1.19 Million
Q1 2021 May 13, 2021	SELL	$16.0 - $24.46 $177,600 - $271,506	-11,100 Closed	0 $0
Q4 2020 Feb 10, 2021	BUY	$15.89 - $40.87 $176,379 - $453,657	11,100 New	11,100 $219,000

Others Institutions Holding RAPT

# of Institutions

148

Shares Held

29.2M

Call Options Held

709K

Put Options Held

1.06M

View Full List

About RAPT Therapeutics, Inc.

Ticker RAPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,656,600
Market Cap $90.5M
Description
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...

More about RAPT

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account